FORWARD-LOOKNG STATEMENTS & DISCLOSURES MAY 3, 2022 © 2022 Esperion. All Rights Reserved – For investor audience only WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing ...

WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? FORWARD-LOOKNG STATEMENTS & DISCLOSURES This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, restructuring and current and planned operational expenses, future operations, commercial products, clinical development including the timing, designs and plans for the CLEAR Outcomes study and its resu ...

Core Insights - Esperion has entered into a settlement agreement with Hetero USA, resolving patent litigation related to the generic version of NEXLETOL, preventing Hetero USA from marketing the generic in the U.S. before April 19, 2040, unless specific circumstances arise [1] - Ongoing patent litigation against other defendants regarding NEXLETOL and NEXLIZET continues, with no assurance on the outcome or potential market entry of generics before the 2040 date [2] Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing and marketing new medicines for patients at risk for cardiovascular disease, specifically offering FDA-approved oral, once-daily, non-statin medications for elevated LDL-C [3] - The company is advancing its next-generation program aimed at developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design and the creation of potent inhibitors [3][4] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, collaborations, and the advancement of its pre-clinical pipeline [4]

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, ...

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to ...

Esperion Therapeutics (ESPR) incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion had reported earnings of 34 cents per share.Esperion generated total revenues of $65 million in the first quarter, reflecting a 53% year-over-year decline. The decrease was due to a one-time settlement-related milestone payment received from Daiichi Sankyo Europe (DSE) in the first quarter of 2024. However, ...

Q1 2025 Earnings Presentation May 6, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, plans for potential future product candida ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas Shrader - BTIG Tanmay Patwardhan - JPMorgan Jason Zemansky - Bank of America Serge Belanger - Needham Paul Choi - Go ...

Esperion Therapeutics (ESPR) Update / Briefing January 22, 2025 12:30 PM ET Speaker0 Good afternoon, and welcome to Experian's virtual KOL event. A question and answer session will follow the formal presentation. As a reminder, this call is being recorded, and a replay will be made available on Experian's website following the conclusion of the event. And now I'd like to turn the call over to Sheldon Koenig, Chief Executive Officer of Esperion. Speaker1 Thank you very much, and good morning, everyone. Welco ...